Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 10/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21351085 | 0.89 | STAT3 (0.51) | STAT3CAPN1KMT2ACTSBACE2 | |
| SCHEMBL21705369 | 0.88 | STAT3 (0.50) | STAT3CAPN1KMT2ACTSBACE2 | |
| SCHEMBL19679843 | 0.84 | APLNR (0.49) | STAT3APLNRACE2 | |
| SCHEMBL21348091 | 0.83 | ACE2 (0.48) | STAT3CAPN1KMT2ACTSBACE2 | |
| SCHEMBL7386429 | 0.82 | ACE (0.55) | KMT2AACE2 | |
| SCHEMBL19685446 | 0.81 | ACE (0.56) | ACE2 | |
| SCHEMBL19685305 | 0.80 | P2RX7 (0.48) | KMT2A | |
| SCHEMBL28346593 | 0.80 | XIAP (0.50) | STAT3CAPN1KMT2ACTSBACE2 | |
| SCHEMBL22300346 | 0.77 | OPRM1 (0.51) | CAPN1KMT2ACTSBAPLNR | |
| SCHEMBL15214200 | 0.77 | OPRM1 (0.52) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707507-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | ADOCIA (FR) | 2023-07-25 | — | — | US | disclosed |
| US-20200306346-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20200046805-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2020-02-13 | — | — | US | disclosed |
| US-10463717-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | ADOCIA (FR) | 2019-11-05 | — | — | US | disclosed |
| US-20190275108-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190274953-A1 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10383918-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid | ADOCIA (FR) | 2019-08-20 | — | — | US | disclosed |
| US-20180193421-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2018-07-12 | — | — | US | disclosed |
| US-20170348394-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170348395-A1 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275108-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GPR119, GLP1R | STAT3 468/4885CAPN1 2370/4885KMT2A 4616/4885 |
| US-20180193421-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | IAPP, GPR119, GIPR | STAT3 472/4885CAPN1 2587/4885KMT2A 4535/4885 |
| US-10463717-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | IAPP, GPR119, GIPR | STAT3 463/4885CAPN1 2664/4885KMT2A 4591/4885 |
| US-20200306346-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, GCGR | STAT3 101/4885CAPN1 3875/4885KMT2A 2543/4885 |
| US-20200046805-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | STAT3 208/4885CAPN1 2328/4885KMT2A 4720/4885 |
| US-20170348394-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A STATISTICAL CO-POLYAMINO ACID | GCG, GLP1R, IAPP | STAT3 102/4885CAPN1 3974/4885KMT2A 2983/4885 |
| US-10383918-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a statistical co-polyamino acid | GCG, GLP1R, IAPP | STAT3 102/4885CAPN1 3974/4885KMT2A 2983/4885 |
| US-20190275110-A1 | COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GLP1R, IAPP | STAT3 100/4885CAPN1 3190/4885KMT2A 3000/4885 |
| US-20170348395-A1 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GLP1R, IAPP | STAT3 98/4885CAPN1 3877/4885KMT2A 2724/4885 |
| US-11707507-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid | IAPP, INSR, GLP1R | STAT3 208/4885CAPN1 2328/4885KMT2A 4720/4885 |
| US-20190274953-A1 | PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI COMPRISED FROM 5.8 TO 8.5 AND A CO-POLYAMINOACIDE BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | GPR119, INSR, GCG | STAT3 172/4885CAPN1 1753/4885KMT2A 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.